In_FW
vivo_FW
modulation_NN
of_IN
glucocorticoid_NN
receptor_NN
mRNA_NN
by_IN
inhaled_VBN
fluticasone_NN
propionate_NN
in_IN
bronchial_JJ
mucosa_NN
and_CC
blood_NN
lymphocytes_NNS
in_IN
subjects_NNS
with_IN
mild_JJ
asthma_NN
._.

BACKGROUND_NN
:_:
In_FW
vivo_FW
regulation_NN
of_IN
the_DT
glucocorticoid_NN
receptor_NN
-LRB-_-LRB-
GR_NN
-RRB-_-RRB-
by_IN
glucocorticoids_NNS
provides_VBZ
a_DT
means_NN
of_IN
modulating_VBG
sensitivity_NN
of_IN
targeted_VBN
cells_NNS
._.

OBJECTIVE_NN
:_:
We_PRP
sought_VBD
to_TO
determine_VB
the_DT
in_FW
vivo_FW
modulation_NN
of_IN
GR_NN
mRNA_NN
expression_NN
by_IN
fluticasone_NN
propionate_NN
-LRB-_-LRB-
FP_NN
-RRB-_-RRB-
in_IN
subjects_NNS
with_IN
mild_JJ
asthma_NN
._.

METHODS_NNS
:_:
Ten_CD
atopic_JJ
asthmatic_JJ
subjects_NNS
were_VBD
treated_VBN
with_IN
FP_NN
250_CD
microg_NN
twice_RB
daily_RB
for_IN
4_CD
weeks_NNS
._.

Before_IN
and_CC
after_IN
treatment_NN
,_,
the_DT
patients_NNS
underwent_VBD
fiberoptic_JJ
bronchoscopy_NN
with_IN
endobronchial_JJ
biopsy_NN
and_CC
sampling_NN
of_IN
venous_JJ
blood_NN
for_IN
measurements_NNS
of_IN
GR_NN
mRNA_NN
levels_NNS
._.

A_DT
solution_NN
hybridization_NN
assay_NN
was_VBD
used_VBN
for_IN
quantitative_JJ
analysis_NN
of_IN
GR_NN
mRNA_NN
._.

In_IN
addition_NN
,_,
a_DT
24-hour_JJ
urinary_JJ
cortisol_NN
excretion_NN
and_CC
an_DT
adrenocorticotropic_JJ
hormone_NN
test_NN
before_IN
and_CC
after_IN
treatment_NN
with_IN
FP_NN
were_VBD
performed_VBN
._.

RESULTS_NNS
:_:
A_DT
high_JJ
interindividual_JJ
variation_NN
in_IN
GR_NN
mRNA_NN
expression_NN
was_VBD
seen_VBN
._.

However_RB
,_,
we_PRP
detected_VBD
a_DT
significant_JJ
reduction_NN
of_IN
the_DT
GR_NN
mRNA_NN
levels_NNS
in_IN
the_DT
endobronchial_JJ
biopsy_NN
specimens_NNS
after_IN
FP_NN
treatment_NN
-LRB-_-LRB-
36.6_CD
+_CC
\/_CD
-_:
23.1_CD
and_CC
25.0_NN
+_CC
\/_NN
-_:
10.9_CD
amol_NN
GR_NN
mRNA\/microg_NN
RNA_NN
,_,
respectively_RB
;_:
P_NN
&lt;_JJR
.01_CD
-RRB-_-RRB-
._.

In_IN
the_DT
peripheral_JJ
blood_NN
lymphocytes_NNS
an_DT
even_RB
more_RBR
striking_JJ
downregulation_NN
of_IN
the_DT
GR_NN
by_IN
its_PRP$
cognate_JJ
ligand_NN
was_VBD
documented_VBN
-LRB-_-LRB-
30.3_CD
+_CC
\/_JJ
-_:
26.5_CD
and_CC
8.8_CD
+_CC
\/_JJ
-_:
5_CD
amol_NN
GR_NN
mRNA\/microg_NN
RNA_NN
,_,
respectively_RB
;_:
P_NN
&lt;_JJR
.001_CD
-RRB-_-RRB-
,_,
possibly_RB
reflecting_VBG
differences_NNS
in_IN
glucocorticoid_NN
sensitivity_NN
between_IN
tissues_NNS
._.

A_DT
small_JJ
but_CC
significant_JJ
reduction_NN
of_IN
the_DT
24-hour_JJ
urinary_JJ
cortisol_NN
excretion_NN
was_VBD
observed_VBN
-LRB-_-LRB-
233_CD
+_CC
\/_JJ
-_:
109_CD
and_CC
157_CD
+_CC
\/_JJ
-_:
66_CD
nmol\/L_NN
,_,
respectively_RB
;_:
P_NN
&lt;_JJR
.01_CD
-RRB-_-RRB-
,_,
whereas_IN
the_DT
feedback_NN
regulation_NN
of_IN
glucocorticoid_NN
synthesis_NN
by_IN
means_NNS
of_IN
the_DT
hypothalamic-pituitary-adrenal_JJ
axis_NN
as_RB
assessed_VBN
by_IN
the_DT
adrenocorticotropic_JJ
hormone_NN
test_NN
remained_VBD
normal_JJ
after_IN
treatment_NN
with_IN
FP_NN
._.

CONCLUSION_NN
:_:
The_DT
results_NNS
in_IN
this_DT
study_NN
confirm_VBP
the_DT
potency_NN
of_IN
the_DT
inhaled_VBN
corticosteroid_NN
FP_NN
and_CC
provide_VBP
evidence_NN
for_IN
a_DT
considerable_JJ
tissue-specific_JJ
interindividual_JJ
variation_NN
in_IN
the_DT
expression_NN
of_IN
the_DT
GR_NN
._.

